An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma

British Journal of Cancer

Volumn 91, Issue 11, 2004, Pages 1873-1879

  Hus, I ^a   Dmoszynska, A ^a   Manko, J ^a   Hus, M ^a   Jawniak, D ^a   Soroka Wojtaszko, M ^a   Hellmann, A ^b   Ciepluch, H ^b   Skotnicki, A ^c   Wolska Smolen, T ^c   Sulek, K ^d   Robak, T ^e   Konopka, L ^d   Kloczko, J ^f  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d CSK WAM ^*  (Poland)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Long term response; Multiple myeloma; Pretreatment parameters; Thalidomide

Indexed keywords

ALBUMIN; BENCE JONES PROTEIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; DEXAMETHASONE; HEMOGLOBIN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; THALIDOMIDE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL EXAMINATION; CONSTIPATION; DEEP VEIN THROMBOSIS; DRUG POTENTIATION; FATIGUE; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LABORATORY TEST; LEUKOPENIA; LIVER FUNCTION TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUROLOGIC EXAMINATION; PARAMETER; PLASMA CELL; POLYNEUROPATHY; PRETREATMENT PARAMETER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RASH; RELAPSE; SOMNOLENCE; TABLET; TREATMENT OUTCOME; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; BETA 2-MICROGLOBULIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 19944428373     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602225     Document Type: Article

References (37)

1. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexamnn R (2003) Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematolo 121: 768-771
2. Ahmad I, Islam T, Chanan -Khan A, Hahn T, Wentling D, Becker JL, McCarthy Jr PL, Alam AR (2002) Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologousPBSCT. Bone Marrow Transplant 27: 577-580
3. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G (2001a) Extended survival in advanced andrefractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in aphase 2 study of 169 patients. Blood 98: 492-494
4. Barlogie B, Tricot G, Anaissie E (2001b) Thalidomide in the management of multiple myeloma. Semin Oncol 28: 577-582
5. Cavenagh JD, Oakervee H (2003) Thalidomide in multiple myeloma-current status and future prospects. Br J Haematol 120: 18-26
6. Cheng D, Kini AR, Rodriguez J, Hurt R, Peterson LC, Tray nor AE (1999) Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients. Blood 94(Suppl 1): 315a
7. Dmoszynska A, Bojarska-Junak A, Domanski D, Rolnski J, Hus M, Soroka-Wojtaszko M (2002) Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymph 43: 401-406
8. Dmoszynska A, Hus M, Legiec W, Walter-Croneck A, Wach M (2000) Delayed stem celltransplantation in patients with relapsed or refractory multiple myeloma using lhalidomide as a preparative regimen. Blood 96(Suppl 1): 5345
9. Dmoszynska A, Hus M, Soroka-Wojtaszko M, Mariko J, Jawniak D, Legiec VV, Grzasko N, Hellmann A, Ciepluch H, Baran W, Skotnicki A, Wolska-Smolen T, Sutek K, Borysewicz-Czajka T, Sawicki W, Robak T, Szmigielska A, Konopka L, Pszenna E, Szpila T, Kloczko J, Piszcz J, Zdziarska B (2003) Multicenter clinical study of thalidomide efficacv in patients with refractory and relapsed multiple myeloma. Hematology J 4(Suppl 1): 226
10. Fonseca R, Conte G, Greipp PR (2001) Laboratory correlates in multiple mveloma: how useful for prognosis? Blood Rex 15: 97-102
11. Garcia-Sanz R, Gonzalez-Poraz JR, Hernandez JM, Polo-Zarzuela M, Surreda A, Barrenetxea C, Palomera L, Lopez R, Grande-Garcia C, Alegre A, Vargas-Pabon M, Gutierez ON, Rodrigez JA, San Miguel JF (2004) The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 18: 856-863
12. Geitz H, Handt S, Zwingenberger K (1996) Thalidomide selectively modulates th density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31: 213-221
13. Ghobrial IM, Dispenzieri A, Bundy KL, Gastineau DA, Rajkumar SV, Therneau TM, Lacv MQ, Witzig TE, Litzow MR, Christensen BR, Hayman S, Pribula CG, Gertz MA (2003) Effect of thalidomide on stem call collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant 32: 587-592
14. Grosbois B, Belissant P, Moreau P, Altal M, Voillat L, Muret P, Pegourie B, Tiab M, Berthou C, Duguet C (2003) Treatment of advanced multiple mveloma (MM) with thalidomide (THAL). Long term folow-up in a prospective study of 121 patients. Hematulogy 4(Suppl 1): 226
15. Haslett PA, Corral LG, Albert M, Kaplan G (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. J Exp Med 187: 1885-1892
16. Hus M, Dmoszyriska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepluch H, Hellmann A, Wolska-Smoleh T, Skotnicki A, Manko J (2001) Thalidomide treatment of resistant or relapsed multiple mveloma patients. Hematologica 86: 404-408
17. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C (2000) Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractor), and relapsed myeloma. Br J Haemalol 109: 89-96
18. Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicv M, Ben-Bassat I (2000) Therapv with thalidomide in refractor) multiple myeloma patients-the revival of an old drug. Br J Haematol 108: 391-393
19. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, Fonesca R, Hayman SR, Lust JA, Kyle RA, Greipp PR, Witzig TE, Rajkumar SV (2003) Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple mveloma. Mayo Clin Proc 78: 34-39
20. Kyle RA, Rajkumar V (2001) Therapeutic application of thalidomide in multiple myeloma. Semin Oncol 28: 583-587
21. Lee FC (2002) Second response to lower-dose thalidomide in a patient with multiple mveloma. Blood 99: 4248
22. Leleu X, Magro L, Fawaz A, Banters F, Facon T, Yacoub-Agha I (2002) Efficacy of a low dose of thalidomide in advanced multiple myeloma. Blood 100: 1519-1520
23. Mileshkin L, Biagi JJ, Mitchel P, Underhill C, Grigg A, Bell R, McKendrick J, Briggs P, Seymour JF, Lillie K, Smith JG, Zeldis JB, Prince HM (2003) Multicenter phase 2 trail of thalidomide in relapsed refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 102: 69-77
24. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smidt KA, Kaplan G (1993) Thalidomide exerts its ihibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177: 1675-1680
25. Neben K, Moehler T, Egerer G, Kraemer A, Hillengass J, Benner A, Mo AD, Goldschmidt H (2001) High plasma basic fibroblast growth factor concentration is aAociaied with response to ihalidomide in progressive multiple myeloma. Clin Cancer Res 7: 2675-2681
26. Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, Goldschmidt H (2002) Dose-dependent effect of thalidomide on overall survival in relapsed multiple mveloma. Clin Cancer Res 8: 3377-3382
27. Offidani M, Marconi M, Corvatta L, Olivieri A, Catarini VI, Leoni (2003) Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. Haematologica 88: 1432-1433
28. Patriarca F, Sperotto A, Prosdocimo S, Geromin A, Zaja F, Fanin R (2003) Thalidomide before autologous stem cell transplantation in VAD-refractorv multiple mveloma patients. Huematologica 88: 597-599
29. Pitini V, Arrigo C, Aloi G, Micali C, La Gattuta G (2003) I halidomide as a salvage therapv for VAD-refractorv multiple myeloma prior to autologous PBSCT. Marrow Transplant 31: 1065
30. Rajkumar SV, Greipp PR (1999) Prognostic factors in multiple myeloma. Hematol Oncol Clin N Am 13: 1295-1314
31. Rajkumar VS, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle R, Witzig TE (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20: 4319-4323
32. Rajkumar SV, Witzig TE (2000) A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 26: 351-362
33. Singhal S, Mehta J, Desikan R, Roberson P, Eddelmon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor acmity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571
34. Turk BO, Jiang H, Liu JO (1996) Binding of thalidomide to alpha I-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci USA 93: 7552-7556
35. Weber DM, Gavino M, Delasalle K, Rankin K, Giralt S, Alexanian R (1999) Thalidomide alone or with dexamethasone for multiple myeloma. Blood 94: 604a
36. Yakoub-Agha I, Altal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M, Harousseau JL, Daguet C, Duhamel A, Facon T (2002) Thalidomide in patients with advanced multiple myeloma: a study of 83 patients-report of the intergroupe francophone du myelome (IFM). Hematology 7: 3:185-3:192
37. Zervas K, Dimopoulos A, Hatzicharissi E, Agruistopoulous A, Papaioannau M, Mitsouli Ch, Panagiotidis P, Korantzis J, Tzilianos M, Maniatis A (2004) Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter studv. Ann Oncol 15: 134-138